Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Henry Schein reports strong Q1 growth despite PPE sales decline

Henry Schein reported strong internal growth despite challenges in PPE and COVID test kit sales. The company's strategic acquisitions and stable European equipment market position it well for future growth. However, pricing pressures and a decline in GAAP operating margin present challenges. Anticipated income growth in the second half of the year and stable medical business present opportunities for the company.

HSIC reports solid Q2 results, anticipates deflation in dental consumables

HSIC's Q2 performance was driven by strong dental and equipment sales, but challenges from COVID-related headwinds and deflation in consumable dental products were noted. The company remains committed to its strategic plan and has identified opportunities in the dental consumable business and technology investments.

HSIC reports solid Q3 results amid cybersecurity challenges and opportunities

HSIC's Q3 performance showcased resilience in the face of a cybersecurity incident, with solid financial results and a focus on customer retention. Challenges persist in customer ordering and operational recovery, but the company remains optimistic about future opportunities and the stability of its business.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Henry Schein (HSIC) sees solid performance by the global Medical and Technology and Value-added Services businesses in Q2.

Henry Schein (HSIC) Q2 Earnings Beat Estimates, Revenues Miss

Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.

Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?

The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.

Henry Schein Closes Acquisition of Elite Computer Italia

West Pharmaceutical Services

HSIC vs. WST: Which Stock Is the Better Value Option?

HSIC vs. WST: Which Stock Should Value Investors Buy Now?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Why Is Henry Schein (HSIC) Down 1.6% Since Last Earnings Report?

Dean Foods

SolarEdge Technologies

See how these three stocks resisted the broader market's decline.

Why Henry Schein, Dean Foods, and SolarEdge Jumped Today

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q1 2019 Results - Earnings Call Transcript

Henry Schein's (HSIC) strong share gains in the North American market raise optimism.

Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates

Henry Schein (HSIC) delivered earnings and revenue surprises of 5.26% and 0.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q1 Earnings and Revenues Beat Estimates

Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.

Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Henry Schein (HSIC) Up 2.1% Since Last Earnings Report?

Henry Schein expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.

Henry Schein's New Buyout to Boost Dental Technology Business

News for Henry Schein Stock (HSIC)